MX2019009640A - Ingrediente activo farmaceutico y uso del mismo, en particular, para la prevencion y el tratamiento de trastornos metabolicos en humanos y animales. - Google Patents

Ingrediente activo farmaceutico y uso del mismo, en particular, para la prevencion y el tratamiento de trastornos metabolicos en humanos y animales.

Info

Publication number
MX2019009640A
MX2019009640A MX2019009640A MX2019009640A MX2019009640A MX 2019009640 A MX2019009640 A MX 2019009640A MX 2019009640 A MX2019009640 A MX 2019009640A MX 2019009640 A MX2019009640 A MX 2019009640A MX 2019009640 A MX2019009640 A MX 2019009640A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
active ingredient
pharmaceutical active
humans
Prior art date
Application number
MX2019009640A
Other languages
English (en)
Inventor
MAUGARD Thierry
Sirvent Pascal
PELTIER Sébastien
Chavanelle Vivien
LE JOUBIOUX Florian
Original Assignee
Valbiotis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valbiotis filed Critical Valbiotis
Publication of MX2019009640A publication Critical patent/MX2019009640A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención se refiere a un ingrediente farmacéutico activo que consiste exclusivamente en la combinación de ácido (1S,3R,4R,5R)-3-{[(2E)-3-(3,4-)dihidroxifenil)-2-propenoil]oxi}-1 ,4,5- trihidroxiciclohexanocarboxílico y metil (2S,3E,4S)-4-{2-[2-(3,4-dihidroxifenil)etoxi]-2-oxoetil}-3- etilideno-2-(ß-D-glucopiranosiloxi)-3,4-dihidro-2H-piran-5-carbox ilato para uso como medicamento o producto veterinario, particularmente en la prevención y/o el tratamiento de trastornos patológicos del metabolismo de carbohidratos y/o lípidos.
MX2019009640A 2017-02-16 2018-02-13 Ingrediente activo farmaceutico y uso del mismo, en particular, para la prevencion y el tratamiento de trastornos metabolicos en humanos y animales. MX2019009640A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1770144A FR3062795B1 (fr) 2017-02-16 2017-02-16 Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal.
PCT/EP2018/053520 WO2018149812A1 (fr) 2017-02-16 2018-02-13 Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal

Publications (1)

Publication Number Publication Date
MX2019009640A true MX2019009640A (es) 2019-10-02

Family

ID=58645316

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009640A MX2019009640A (es) 2017-02-16 2018-02-13 Ingrediente activo farmaceutico y uso del mismo, en particular, para la prevencion y el tratamiento de trastornos metabolicos en humanos y animales.

Country Status (18)

Country Link
US (1) US11191744B2 (es)
EP (1) EP3582767B1 (es)
JP (2) JP2020509998A (es)
KR (1) KR20190130572A (es)
CN (1) CN110520120A (es)
AU (1) AU2018221616A1 (es)
BR (1) BR112019016945A2 (es)
CA (1) CA3051789A1 (es)
ES (1) ES2879318T3 (es)
FR (1) FR3062795B1 (es)
IL (1) IL268271A (es)
MA (1) MA47498B1 (es)
MX (1) MX2019009640A (es)
PL (1) PL3582767T3 (es)
RU (1) RU2759903C2 (es)
SG (1) SG11201906907TA (es)
WO (1) WO2018149812A1 (es)
ZA (1) ZA201905309B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11152221B2 (en) 2019-02-20 2021-10-19 Applied Materials, Inc. Methods and apparatus for metal silicide deposition
IT202100031985A1 (it) * 2021-12-21 2023-06-21 Innbiotec Pharma S R L Composizione farmaceutica a base di glutatione tioestere e oleuropeina per l’uso nel trattamento della steatoepatite non alcolica

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070009620A1 (en) * 2005-07-11 2007-01-11 Yoshinori Aoki Cholesterol regulating agent
US20090061031A1 (en) * 2006-07-07 2009-03-05 Sylvia Lee-Huang Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus
CA2705785A1 (en) * 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
CN100502854C (zh) * 2007-01-23 2009-06-24 武汉大学 绿原酸在制备抗糖尿病并发症的药中的应用
ITMI20080514A1 (it) * 2008-03-27 2009-09-28 Univ Firenze Uso della oleuropeina e suoi derivati nel trattamento del diabete mellito di tipo 2 e di patologie associate a fenomeni di aggregazione di proteine
RU2451506C1 (ru) * 2011-06-02 2012-05-27 Сергей Юрьевич Лешков Комбинация для лечения сахарного диабета и его осложнений
FR3027228B1 (fr) * 2014-10-20 2016-12-09 Valbiotis Composition comprenant un melange d'extraits vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique

Also Published As

Publication number Publication date
JP2020509998A (ja) 2020-04-02
AU2018221616A1 (en) 2019-08-08
JP2022180477A (ja) 2022-12-06
WO2018149812A1 (fr) 2018-08-23
MA47498B1 (fr) 2021-08-31
RU2019125320A (ru) 2021-03-16
EP3582767A1 (fr) 2019-12-25
RU2759903C2 (ru) 2021-11-18
PL3582767T3 (pl) 2021-11-08
IL268271A (en) 2019-09-26
RU2019125320A3 (es) 2021-05-20
ES2879318T3 (es) 2021-11-22
CA3051789A1 (fr) 2018-08-23
ZA201905309B (en) 2020-05-27
KR20190130572A (ko) 2019-11-22
EP3582767B1 (fr) 2021-04-07
BR112019016945A2 (pt) 2020-04-14
FR3062795B1 (fr) 2019-06-07
US20200009101A1 (en) 2020-01-09
CN110520120A (zh) 2019-11-29
FR3062795A1 (fr) 2018-08-17
SG11201906907TA (en) 2019-08-27
US11191744B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
MX2016000307A (es) Farmaco para el tratamiento de la esteatosis hepatica no alcoholica.
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
MA49023A (fr) Application d'un composé ou d'un extrait de médecine chinoise traditionnelle dans la préparation d'un agent d'administration d'acide nucléique et produits apparentés correspondants
BR112017021439A2 (pt) sistema de microagulha para aplicar formulações líquidas
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
MA28778B1 (fr) Compositions de risedronate et procede d'utilisation de celle-ci
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
UA101393C2 (ru) КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ТРИАЗОЛА ДЛЯ ЛЕЧЕНИЯ β-АМИЛОИДОЗОВ И СИНУКЛЕИНОПАТИЙ
MX2019009640A (es) Ingrediente activo farmaceutico y uso del mismo, en particular, para la prevencion y el tratamiento de trastornos metabolicos en humanos y animales.
BR112018073951A2 (pt) forma cristalina inovadora de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-1-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
BR112014027676A2 (pt) formulação de cápsula solubilizada de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metóxi-isoquinolin-1-ilóxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletila
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
UY28209A1 (es) Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos.
CY1116274T1 (el) Παραγωγο τριαζολιου για χρηση στη θεραπεια του νευροπαθητικου πονου και της ινομυαλγιας
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP3818981A4 (en) SYNERGIC PHARMACEUTICAL COMBINATION OF THE ACTIVE ENANTIOMER S-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAIN
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
WO2009070045A3 (en) Imidazole derivatives, process for their preparation, and thier pharmaceutical use
WO2006053791A3 (en) Compounds that modulate ppary type receptors, and use thereof in cosmetic or pharmaceutical compositions
WO2006089120A3 (en) Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury